Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Decision analysis of treatment strategies in children with severe sickle cell disease.

O'Brien SH, Hankins JS.

J Pediatr Hematol Oncol. 2009 Nov;31(11):873-8. doi: 10.1097/MPH.0b013e3181b83cab.

2.

Principles and indications of chronic transfusion therapy for children with sickle cell disease.

Ware R.

Clin Adv Hematol Oncol. 2007 Sep;5(9):686-8. Review. No abstract available.

PMID:
17982409
3.

Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE.

Blood. 1999 Sep 1;94(5):1550-4.

4.

Use of hydroxyurea in prevention of stroke in children with sickle cell disease.

Lefèvre N, Dufour D, Gulbis B, Lê PQ, Heijmans C, Ferster A.

Blood. 2008 Jan 15;111(2):963-4; author reply 964. doi: 10.1182/blood-2007-08-102244. No abstract available.

5.

Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?

Creary SE, Chisolm DJ, Koch TL, Zigmont VA, Lu B, O'Brien SH.

Pediatr Blood Cancer. 2016 May;63(5):844-7. doi: 10.1002/pbc.25894. Epub 2016 Jan 21.

6.

Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment.

Lê PQ, Gulbis B, Dedeken L, Dupont S, Vanderfaeillie A, Heijmans C, Huybrechts S, Devalck C, Efira A, Dresse MF, Rozen L, Benghiat FS, Ferster A.

Pediatr Blood Cancer. 2015 Nov;62(11):1956-61. doi: 10.1002/pbc.25608. Epub 2015 Jul 14.

PMID:
26173735
7.

Clinical and laboratory effects of hydroxyurea in children and adolescents with sickle cell anemia: a Portuguese hospital study.

Braga LB, Ferreira AC, Guimarães M, Nazário C, Pacheco P, Miranda A, Picanço I, Seixas T, Rosado L, Amaral JM.

Hemoglobin. 2005;29(3):171-80.

PMID:
16114180
8.

Therapy preference and decision-making among patients with severe sickle cell anemia and their families.

Hankins J, Hinds P, Day S, Carroll Y, Li CS, Garvie P, Wang W.

Pediatr Blood Cancer. 2007 Jun 15;48(7):705-10.

PMID:
16732581
9.

Challenge of managing sickle cell disease in a pediatric population living in kinshasa, democratic republic of congo: a sickle cell center experience.

Aloni MN, Nkee L.

Hemoglobin. 2014;38(3):196-200. doi: 10.3109/03630269.2014.896810. Epub 2014 Mar 26.

PMID:
24669956
10.
11.
12.

The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.

Kassim AA, DeBaun MR.

Expert Opin Pharmacother. 2014 Feb;15(3):325-36. doi: 10.1517/14656566.2014.868435. Epub 2014 Jan 7. Review.

PMID:
24392871
13.

When should hydroxyurea be used for children with sickle cell disease?

Mueller BU.

Pediatrics. 2008 Dec;122(6):1365-6. doi: 10.1542/peds.2008-1058. No abstract available.

PMID:
19047256
14.

Periodic erythroexchange is an effective strategy for high risk paediatric patients with sickle-cell disease.

Masera N, Tavecchia L, Pozzi L, Riva F, Vimercati C, Calabria M, Ronzoni S, Masera G, Perseghin P.

Transfus Apher Sci. 2007 Dec;37(3):241-7. Epub 2007 Nov 26.

PMID:
18042436
15.

Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy.

Nickel RS, Osunkwo I, Garrett A, Robertson J, Archer DR, Promislow DE, Horan JT, Hendrickson JE, Kean LS.

Br J Haematol. 2015 May;169(4):574-83. doi: 10.1111/bjh.13326. Epub 2015 Mar 5.

16.

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.

Medicine (Baltimore). 1996 Nov;75(6):300-26.

17.

Mortality in sickle cell patients on hydroxyurea therapy.

Bakanay SM, Dainer E, Clair B, Adekile A, Daitch L, Wells L, Holley L, Smith D, Kutlar A.

Blood. 2005 Jan 15;105(2):545-7. Epub 2004 Sep 28.

18.

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Blood. 2010 Mar 25;115(12):2354-63. doi: 10.1182/blood-2009-05-221333. Epub 2009 Nov 10.

19.

Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities.

Brandow AM, Panepinto JA.

Expert Rev Hematol. 2010 Jun;3(3):255-60. doi: 10.1586/ehm.10.22. No abstract available.

20.

Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.

Narang I, Kadmon G, Lai D, Dhanju S, Kirby-Allen M, Odame I, Amin R, Lu Z, Al-Saleh S.

Ann Am Thorac Soc. 2015 Jul;12(7):1044-9. doi: 10.1513/AnnalsATS.201410-473OC.

PMID:
25970812

Supplemental Content

Support Center